Mohamed Y. Elwazir

Mohamed Y. Elwazir

Auto-generated profile, based on publicly available information

Mohamed Y. Elwazir

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2019 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
AWAndrew Wen
Andrew Wen
SFSunyang Fu
Sunyang Fu
SMSungrim Moon
Sungrim Moon
MWMohamed El Wazir
Mohamed El Wazir
ARAndrew Rosenbaum
Andrew Rosenbaum
JFJungwei Fan
Jungwei Fan
Data is foundational to high-quality artificial intelligence (AI). Given that a substantial amount of clinically relevant information is embedded in unstructured data, natural language processing (NLP) plays an essential role in extracting valuable information that can benefit decision making, administration reporting, and research. Here, we share several desiderata pertaining to development and usage of NLP systems, derived from two decades of experience implementing clinical NLP at the Mayo Clinic, to inform the healthcare AI community. Using a framework, we developed as an example implementation, the desiderata emphasize the importance of a user-friendly platform, efficient collection of domain expert inputs, seamless integration with clinical data, and a highly scalable computing infrastructure.

1 February 2022 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
MEMohamed Elwazir
Mohamed Elwazir
MKMegan L. Krause
Megan L. Krause
JBJohn P. Bois
John P. Bois
GCGeorgios Christopoulos
Georgios Christopoulos
AKAyse T. Kendi
Ayse T. Kendi
SAShreyasee Amin
Shreyasee Amin

21 August 2020 in ASAIO Journal
Verified
Journal Article
Closed access
TSTyler J. Schmidt
Tyler J. Schmidt
ARAndrew N. Rosenbaum
Andrew N. Rosenbaum
NKNikhil Kolluri
Nikhil Kolluri
JSJohn M. Stulak
John M. Stulak
RDRichard C. Daly
Richard C. Daly
LBLori A. Blauwet
Lori A. Blauwet
To our knowledge, natural history has not been reported for cardiac sarcoidosis (CS) diagnosed by pathologic evaluation of the apical core at left ventricular assist device (LVAD) implantation or cardiac transplantation. We retrospectively identified 232 consecutive patients meeting CS criteria. Of these patients, 54 were diagnosed by pathologic confirmation of CS, 10 after evaluation of the apical core (LVAD implant) or explanted heart (transplant). We compared clinical characteristics at initial evaluation and outcomes for these 10 patients with those of 10 patients with known CS before LVAD implant/transplant. In the study group, five patients (50%) had confirmed extracardiac sarcoidosis before LVAD implant/transplant; five had not been diagnosed with sarcoidosis. Mean (standard deviation) left ventricular ejection fraction at initial evaluation was 23% (16%), and left ventricular end-diastolic dimension was 61 (10) mm. Four patients died during follow-up; however, no survival difference was found for the 10 patients diagnosed incidentally and the group with a previous diagnosis or institutional LVAD/transplant cohorts. Patients diagnosed with CS on pathological examination of the apical core/explanted heart may have severe dilated cardiomyopathy as the initial presentation. Outcomes for patients with CS after advanced heart failure therapies may be comparable with those of non-CS patients.

1 July 2020 in Seminars in Nuclear Medicine
Verified
Journal Article
Open access
MEMohamed Y. Elwazir
Mohamed Y. Elwazir
JBJohn P. Bois
John P. Bois
OEOmar F. Abou Ezzeddine
Omar F. Abou Ezzeddine
PCPanithaya Chareonthaitawee
Panithaya Chareonthaitawee
Cardiac sarcoidosis (CS) refers to the increasingly recognized cardiac involvement of an incompletely understood systemic disease entity-sarcoidosis. Endomyocardial biopsy can provide definitive diagnosis but is limited by its invasiveness and poor sensitivity. In the absence of a reliable gold standard, a combination of clinical, electrocardiographic, imaging, and histologic criteria are relied upon to provide probabilistic diagnosis. Within the last few years, societal documents have included advanced cardiovascular imaging modalities, 18F-FDG-PET/CT and cardiac magnetic resonance in their diagnostic algorithms. The current article provides a review of the imaging modalities used for screening and detection of CS, highlighting the principal findings of each with a specific focus on quantification, whenever applicable, and concluding with a proposed approach to the imaging of patients with suspected CS.

1 June 2021 in The American Journal of Cardiology
Verified
Journal Article
Open access
NKNikhil Kolluri
Nikhil Kolluri
MEMohamed Y. Elwazir
Mohamed Y. Elwazir
ARAndrew N. Rosenbaum
Andrew N. Rosenbaum
FMFathi A. Maklady
Fathi A. Maklady
OAOmar F. AbouEzzeddine
Omar F. AbouEzzeddine
JBJohn P. Bois
John P. Bois
Sarcoidosis is a multisystem inflammatory condition with occasional cardiac involvement (CS), which may be associated with risk of venous thromboembolism (VTE). As data on VTE in CS are sparse and corticosteroid therapy has not been previously examined, we aim to determine the association between CS, corticosteroid treatment for CS, and VTE. Patients referred to our institution with concern for sarcoidosis and underwent a positron emission tomography (PET) scan were retrospectively assessed. Chi-squared and multivariate regression analyses were conducted to determine the association between a diagnosis of sarcoidosis, CS, corticosteroid use, and VTE events. Six hundred and forty nine patients were split into three categories: 235 with no sarcoidosis (NS), 91 with extra-cardiac sarcoidosis only (ECS), and 323 with CS (isolated CS and/or CS with extra cardiac sarcoid). Thirty nine CS, 7 ECS, and 9 NS patients developed PE while 44 CS, 3 ECS, and 18 NS patients developed DVT. On multivariate regression, neither CS nor ECS was an independent risk factor for VTE (p>0.05) but corticosteroid use was independently associated with VTE (HR 3.06, p=0.007 for PE, HR 6.21, p<0.0001 for DVT). On logistic regression analysis, corticosteroid dose was found to be independently associated with both PE (p=0.001) and DVT (p=0.007). Optimal threshold for defining VTE risk with corticosteroid therapy was a prednisone-equivalent dose of 17.5 mg. In conclusion, contrary to previous studies, this current study found that neither sarcoidosis nor CS is an independent risk factor for VTE. Rather, corticosteroid therapy was associated with an increased risk of VTE.

1 January 2020 in Journal of Microscopy and Ultrastructure
Verified
Journal Article
Open access
MEMohamedY Elwazir
MohamedY Elwazir
SHSomaya Hosny
Somaya Hosny
Artificial intelligence has found its way into numerous fields of medicine in the past decade, spurred by the availability of big data and powerful processors. For the COVID-19 pandemic, aside from predicting its onset, artificial intelligence has been used to track disease spread, detect pulmonary involvement in computed tomography scans, risk-stratify patients, and model virtual protein structure and potential therapeutic agents. This mini-review briefly discusses the potential applications of artificial intelligence in COVID-19 microscopy.